Anest. intenziv. Med. 2014;25(1):21-24

Myasthenia gravis and anaesthesia - a new and safer approachAnaesthesiology - Review articles

Vymazal Tomáš*, Horáček Michal, Bicek Vladimír, Filaun Martin
Klinika anesteziologie, resuscitace a intenzivní medicíny 2. lékařské fakulty Univerzity Karlovyve Fakultní nemocnici v Motole, Praha

Myasthenia gravis impairs neuromuscular transmission. Its therapy is pharmacological, immunological and surgical by thymectomy. Surgery, anaesthesia and other factors can induce exacerbation of myasthenia. The safest technique of anaesthesia has not been determined. Anaesthesia without muscle relaxation recommended, either deep inhalational anaesthesia, or propofol with opioids, or regional anaesthesia. If neuromuscular blocking agents are needed to create a motionless surgical field, the main problem is neuromuscular transmission impairment. Myasthenic patients react on these agents unpredictably. The most feared complication is a prolonged effect preventing spontaneous ventilation with an increased risk of aspiration and a decreased reaction to hypoxia. In these circumstances mechanical ventilation can be continued. Pharmacological reversal can be attempted but it can induce a cholinergic crisis and its effect is usually limited. A new possibility is the use of rocuronium for muscle relaxation with reversal by sugammadex. Rocuronium and sugammadex could offer a new, effective and safe approach to general anaesthesia in myasthenic patients.

Keywords: general anaesthesia; myasthenia gravis; neuromuscular junction; rocuronium; sugammadex

Published: February 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vymazal T, Horáček M, Bicek V, Filaun M. Myasthenia gravis and anaesthesia - a new and safer approach. Anest. intenziv. Med. 2014;25(1):21-24.
Download citation

References

  1. McGrogan, A., Sneddon, S., de Vries, C. S. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology, 2010, 34, p. 171-183. Go to original source... Go to PubMed...
  2. Špalek, P. Myastenia gravis. Cesk. Slov. Neurol. N., 2008, 104, 71, p. 7-24.
  3. Jani-Acsadi, A., Lisak, R. P. Myasthenia Gravis. Current Treatment Options in Neurology, 2010, 12, p. 231-243. Go to original source... Go to PubMed...
  4. Gritti, P., Sgarzi, M., Carrara, B., Laterna, L. A., Novellino, L., Spinelli, L. et al. A standardized protocol for the perioperative management of myasthenia gravis patients. Experience with 110 patients. Acta Anaesthesiol. Scand., 2012, 56, p. 66-75. Go to original source... Go to PubMed...
  5. Černý, V., Adamus, M., Cvachovec, K., Ševčík, P., Herold, I. Anestezie v České republice 2010 - jednodenní prospektivní observační dotazníková studie. Anest. intenziv. Med., 2011, 22, p. 5-12.
  6. Rudzka-Nowak, A., Piechota, M. Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex. Arch. Med. Sci., 2011, 7, p. 361-364. Go to original source... Go to PubMed...
  7. Souhrn údajů o přípravku BRIDION 100 mg/ml injekční roztok (revize textu 27.2.2012).
  8. Sungur, Ulke Z., Yavru, A., Camci, E., Ozkan, B., Toker, A., Senturk, M. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol. Scand., 2013, publikováno elektronicky předem (doi: 10.1111/aas.12123). Go to original source... Go to PubMed...
  9. Kiss, G., Lacour, A., d'Hollander, A. Fade of train-of-four ratio despite administration of more than 12 mg kg-1 sugammadex in a myasthenia gravis patient receiving rocuronium. Br. J. Anaesth., 2013, 110, p. 854-855. Go to original source... Go to PubMed...
  10. Nakamori, E., Nitahara, K., Sugi, Y., Katori, K., Matsu-zaki, A., Higa, K. Reversal of rocuronium induced neuromuscular block with sugammadex in a patient with myasthenia gravis. Masui., 2013, 62, p. 972-974. Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.